Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476775 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30037693 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL18917031 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30801428 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL417576 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL29388642 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30059530 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL2477982 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL128589 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL3161061 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117042748-A | Inverse emulsion comprising at least one fatty alcohol, a nonionic sugar ester, ethylcellulose, and a method employing the inverse emulsion | 莱雅公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116349679-A | Composite disinfection and sterilization method | 孙国明 | 2023-06-30 | — | — | CN | claimed |
| CN-102014872-A | Compositions and methods for reducing or preventing water loss from the skin | SCHERING PLOUGH HEALTHCARE | 2011-04-13 | — | — | CN | claimed |
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | claimed |
| EP-1648364-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MacroChem Corporation (US) | 2006-04-26 | — | — | EP | claimed |
| CN-1195512-C | Use of fatty materials for prevention or reduction of microorganism adhere on skin and/or mucous membrane | OREAL (FR) | 2005-04-06 | — | — | CN | claimed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| CN-1174037-C | Gel composition | �����ɺϻ﹫˾ | 2004-11-03 | — | — | CN | claimed |
| CN-1324380-A | Gel composition | PENRECO (US) | 2001-11-28 | — | — | CN | claimed |
| CN-1313086-A | Use of fatty materials for prevention or reduction of microorganism adhere on skin and/or mucous membrane | OREAL (FR) | 2001-09-19 | — | — | CN | claimed |
| US-20240396076-A1 | LITHIUM ION SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTIC SOLUTION | KYOCERA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| CN-119013028-A | Compositions and methods for ameliorating sexual dysfunction | 温桑托尔公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114401707-B | Gel composition with high oil content and preparation method and application thereof | 巴斯夫欧洲公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4398365-A1 | LITHIUM ION SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SOLUTION | Kyocera Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-117836993-A | Lithium ion secondary battery and nonaqueous electrolyte | 京瓷株式会社 | 2024-04-05 | — | — | CN | disclosed |
| CN-1455661-A | Novel cosmetic, personal care, detergent and nutritional supplement compositions containing bioactive glass and methods of making and using the same | SCHOTT GLAS (DE) | 2003-11-12 | — | — | CN | disclosed |
| EP-1311018-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| CN-1324380-A | Gel composition | PENRECO (US) | 2001-11-28 | — | — | CN | disclosed |
| CN-1313086-A | Use of fatty materials for prevention or reduction of microorganism adhere on skin and/or mucous membrane | OREAL (FR) | 2001-09-19 | — | — | CN | disclosed |
| CN-1249172-A | Cosmetics composition contg. silicon deriv. having benzotriazole functional group and triester of benzenetricarboxylic acid, and use thereof | OREAL (FR) | 2000-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | NAAA 2967/4885EPHX1 191/4885TSHR 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.